Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid

Ghulam Abbas, Keith Lindor

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Importance of the field: Primary biliary cirrhosis is a cholestatic liver disease that at one time was the leading indication for liver transplantation. Treatment with ursodeoxycholic acid has clearly improved the natural history of primary biliary cirrhosis. Areas covered in this review: The treatment of primary biliary cirrhosis with a focus on ursodeoxycholic acid is covered. Papers related to treatment of primary biliary cirrhosis and associated conditions, using a variety of drugs but with a focus on ursodeoxycholic acid, are included. The papers reviewed date from 1984 2009. What will the reader gain: The reader will gain an up-to-date understanding of current treatment strategies for primary biliary cirrhosis using ursodeoxycholic acid and an appreciation of what conditions are improved with this therapy and what associated conditions are not. Take-home message: Ursodeoxycholic acid in a dose of 13 15 mg/kg/day should be considered in all patients with primary biliary cirrhosis who have abnormal liver enzymes.

Original languageEnglish (US)
Pages (from-to)387-392
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number3
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Pharmacology
Therapeutics
Liver Transplantation
Liver Diseases
Liver
Enzymes
Pharmaceutical Preparations

Keywords

  • Liver disease
  • Primary biliary cirrhosis
  • Therapy
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. / Abbas, Ghulam; Lindor, Keith.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 3, 02.2010, p. 387-392.

Research output: Contribution to journalArticle

@article{c5800f1708944752967138ef4d7d5957,
title = "Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid",
abstract = "Importance of the field: Primary biliary cirrhosis is a cholestatic liver disease that at one time was the leading indication for liver transplantation. Treatment with ursodeoxycholic acid has clearly improved the natural history of primary biliary cirrhosis. Areas covered in this review: The treatment of primary biliary cirrhosis with a focus on ursodeoxycholic acid is covered. Papers related to treatment of primary biliary cirrhosis and associated conditions, using a variety of drugs but with a focus on ursodeoxycholic acid, are included. The papers reviewed date from 1984 2009. What will the reader gain: The reader will gain an up-to-date understanding of current treatment strategies for primary biliary cirrhosis using ursodeoxycholic acid and an appreciation of what conditions are improved with this therapy and what associated conditions are not. Take-home message: Ursodeoxycholic acid in a dose of 13 15 mg/kg/day should be considered in all patients with primary biliary cirrhosis who have abnormal liver enzymes.",
keywords = "Liver disease, Primary biliary cirrhosis, Therapy, Ursodeoxycholic acid",
author = "Ghulam Abbas and Keith Lindor",
year = "2010",
month = "2",
doi = "10.1517/14656560903493460",
language = "English (US)",
volume = "11",
pages = "387--392",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid

AU - Abbas, Ghulam

AU - Lindor, Keith

PY - 2010/2

Y1 - 2010/2

N2 - Importance of the field: Primary biliary cirrhosis is a cholestatic liver disease that at one time was the leading indication for liver transplantation. Treatment with ursodeoxycholic acid has clearly improved the natural history of primary biliary cirrhosis. Areas covered in this review: The treatment of primary biliary cirrhosis with a focus on ursodeoxycholic acid is covered. Papers related to treatment of primary biliary cirrhosis and associated conditions, using a variety of drugs but with a focus on ursodeoxycholic acid, are included. The papers reviewed date from 1984 2009. What will the reader gain: The reader will gain an up-to-date understanding of current treatment strategies for primary biliary cirrhosis using ursodeoxycholic acid and an appreciation of what conditions are improved with this therapy and what associated conditions are not. Take-home message: Ursodeoxycholic acid in a dose of 13 15 mg/kg/day should be considered in all patients with primary biliary cirrhosis who have abnormal liver enzymes.

AB - Importance of the field: Primary biliary cirrhosis is a cholestatic liver disease that at one time was the leading indication for liver transplantation. Treatment with ursodeoxycholic acid has clearly improved the natural history of primary biliary cirrhosis. Areas covered in this review: The treatment of primary biliary cirrhosis with a focus on ursodeoxycholic acid is covered. Papers related to treatment of primary biliary cirrhosis and associated conditions, using a variety of drugs but with a focus on ursodeoxycholic acid, are included. The papers reviewed date from 1984 2009. What will the reader gain: The reader will gain an up-to-date understanding of current treatment strategies for primary biliary cirrhosis using ursodeoxycholic acid and an appreciation of what conditions are improved with this therapy and what associated conditions are not. Take-home message: Ursodeoxycholic acid in a dose of 13 15 mg/kg/day should be considered in all patients with primary biliary cirrhosis who have abnormal liver enzymes.

KW - Liver disease

KW - Primary biliary cirrhosis

KW - Therapy

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=76449096992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76449096992&partnerID=8YFLogxK

U2 - 10.1517/14656560903493460

DO - 10.1517/14656560903493460

M3 - Article

C2 - 20102304

AN - SCOPUS:76449096992

VL - 11

SP - 387

EP - 392

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 3

ER -